Feasibility Study of Exercise in Patients With Leg Blood Clots
NCT ID: NCT00910364
Last Updated: 2017-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2008-10-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)
NCT03465735
Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
NCT02148029
Full-Leg vs Below-Knee Elastic Stockings for Prevention of the Post-Thrombotic Syndrome
NCT00426075
Below Knee DVT Study
NCT03805672
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
NCT06440694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PTS, caused by persistent venous outflow obstruction and venous valvular dysfunction, may result in symptoms of leg pain, swelling, heaviness and cramping especially with prolonged standing.
All eligible patients with documented first-episode DVT interested in participating will undergo medical screening and a screening treadmill test prior to enrollment between two and four weeks post DVT diagnosis. All patients will be provided and asked to wear class II (30 to 40mmHg) knee length compression hose daily during the entire trial.
The formal exercise training includes both a supervised walking program and a home-based walking program for 12 weeks with follow-up at 26 weeks. Blood tests will be taken to measure levels of indicators of inflammation at baseline, week 4, week 12, and week 26. The primary outcomes will be the feasibility of the exercise program and the incidence of post-thrombotic syndrome at 26 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise testing
Feasibility study; all participants receive intervention
Exercise
Exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
Exercise
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with LMWH, or unfractionated heparin (UFH) followed by warfarin adjusted to keep INR 2 to 3 for at least 3 months, or LMWH given in therapeutic doses as sole therapy.
* Age 21 to 75 years old.
Exclusion Criteria
* Treatment of DVT with systemic or catheter-directed thrombolysis Contraindications to exercise training according to the American College of Sports Medicine (e.g., acute myocardial infarction, unstable angina, etc.,).
* Life expectancy \< 1 year.
* Pregnancy.
* Geographic inaccessibility.
* Screening (pre-randomization) exercise stress test demonstrating contraindication to exercise training (see exclusion #2).
* Cognitive dysfunction assessed by mini-mental status exam (score \< 24).
* Inability to walk.
21 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oklahoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Suman Rathbun
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suman W. Rathbun, M.D.
Role: PRINCIPAL_INVESTIGATOR
Oklahoma University Health Sciences Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ORA #20081607
Identifier Type: OTHER
Identifier Source: secondary_id
14181
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.